BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005;54:782-8. [PMID: 15888785 DOI: 10.1136/gut.2004.056358] [Cited by in Crossref: 169] [Cited by in F6Publishing: 164] [Article Influence: 9.9] [Reference Citation Analysis]
Number Citing Articles
1 Bourgonje AR, Wichers SJ, Hu S, van Dullemen HM, Visschedijk MC, Faber KN, Festen EAM, Dijkstra G, Samsom JN, Weersma RK, Spekhorst LM. Proteomic analyses do not reveal subclinical inflammation in fatigued patients with clinically quiescent inflammatory bowel disease. Sci Rep 2022;12:14581. [PMID: 36028644 DOI: 10.1038/s41598-022-17504-5] [Reference Citation Analysis]
2 Ranjan MK, Vuyyuru SK, Kante B, Kumar P, Mundhra SK, Golla R, Sharma R, Sahni P, Das P, Makharia G, Kedia S, Ahuja V. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease. Int J Colorectal Dis 2022. [PMID: 35835862 DOI: 10.1007/s00384-022-04216-5] [Reference Citation Analysis]
3 Bhala N, Hart A, Watts D, Lewis S, Ghosh S, Hansell C, Ahmad T, Van Haaren S, Sensky T. Disease activity, burden and suffering in patients with ulcerative colitis in the UK cohort recruited into the global ICONIC study. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2022-102104] [Reference Citation Analysis]
4 Long MD, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, Cohen BL, Ungaro RC, Harlan W, Hanson J, Konijeti G, Polyak S, Ritter T, Salzberg B, Seminerio J, English E, Zhang X, Sharma PP, Herfarth HH. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflamm Bowel Dis 2022:izac121. [PMID: 35700276 DOI: 10.1093/ibd/izac121] [Reference Citation Analysis]
5 Liang C, Chen P, Tang Y, Zhang C, Lei N, Luo Y, Duan S, Zhang Y. Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial. Front Psychiatry 2022;13:880058. [DOI: 10.3389/fpsyt.2022.880058] [Reference Citation Analysis]
6 Honap S, Al-hillawi L, Baillie S, Bancil A, Matini L, Lau R, Kok KB, Patel K, Walsh A, Irving PM, Samaan MA. Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2022-102168] [Reference Citation Analysis]
7 Park YE, Moon HS, Yong D, Seo H, Yang J, Shin TS, Kim YK, Kim JR, Lee YN, Kim YH, Kim JS, Cheon JH. Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases. Sci Rep 2022;12:6359. [PMID: 35428806 DOI: 10.1038/s41598-022-10450-2] [Reference Citation Analysis]
8 Ben-shatach Z, Ziv-baran T, Fudim E, Yavzori M, Picard O, Levartovsky A, Selinger L, Weiss B, Kopylov U, Eliakim R, Ungar B. Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening. Therap Adv Gastroenterol 2022;15:175628482210833. [DOI: 10.1177/17562848221083395] [Reference Citation Analysis]
9 Larsen MD, Nørgård BM, Kjeldsen J. Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis? Inflamm Bowel Dis 2022:izab331. [PMID: 34977919 DOI: 10.1093/ibd/izab331] [Reference Citation Analysis]
10 Bakshi N, Hart AL, Lee MC, Williams ACC, Lackner JM, Norton C, Croft P. Chronic pain in patients with inflammatory bowel disease. Pain 2021;162:2466-71. [PMID: 34534174 DOI: 10.1097/j.pain.0000000000002304] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Ellrichmann M, Bethge J, Boesenkoetter J, Conrad C, Noth R, Bahmer T, Nikolaus S, Aden K, Zeissig S, Schreiber S. Subclinical Pulmonary Involvement in Active IBD Responds to Biologic Therapy. J Crohns Colitis 2021;15:1339-45. [PMID: 33544122 DOI: 10.1093/ecco-jcc/jjab024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Ghosh S, Sanchez Gonzalez Y, Zhou W, Clark R, Xie W, Louis E, Loftus EV Jr, Panes J, Danese S. Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. J Crohns Colitis 2021:jjab099. [PMID: 34107013 DOI: 10.1093/ecco-jcc/jjab099] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
13 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Klusmann B, Fleer J, Tovote KA, Weersma RK, van Dullemen HM, Dijkstra G, Schroevers MJ. Trajectories of Fatigue in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab007. [PMID: 33769489 DOI: 10.1093/ibd/izab007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Walsh A, Cao R, Wong D, Kantschuster R, Matini L, Wilson J, Kormilitzin A, South M, Travis S, Bauermeister S. Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis. BMC Gastroenterol 2021;21:132. [PMID: 33752610 DOI: 10.1186/s12876-021-01621-y] [Reference Citation Analysis]
16 Furihata K, Ishiguro Y, Yoshimura N, Ito H, Katsushima S, Kaneko E, Shimabe M, Mukai M, Watanabe R, Morishige T. A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis. Clin Pharmacol Drug Dev 2021;10:870-83. [PMID: 33512065 DOI: 10.1002/cpdd.918] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Xu Y, Qiao YQ, Li HY, Zhou M, Cai CW, Shen J, Ran ZH. NUDT15 genotyping during azathioprine treatment in patients with inflammatory bowel disease: implications for a dose-optimization strategy. Gastroenterol Rep (Oxf) 2020;8:437-44. [PMID: 33442476 DOI: 10.1093/gastro/goaa021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Sakurai T, Nishiyama H, Sakai K, De Velasco MA, Nagai T, Komeda Y, Kashida H, Okada A, Kawai I, Nishio K, Ogata H, Kudo M. Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis. Sci Rep 2020;10:19186. [PMID: 33154436 DOI: 10.1038/s41598-020-76175-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
21 Hoffmann P, Globig AM, Thomann AK, Grigorian M, Krisam J, Hasselblatt P, Reindl W, Gauss A. Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study. J Clin Med 2020;9:E2177. [PMID: 32664204 DOI: 10.3390/jcm9072177] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
22 Samaan MA, Cunningham G, Tamilarasan AG, Beltran L, Pavlidis P, Ray S, Mawdsley J, Anderson SH, Sanderson JD, Arkir Z, Irving PM. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study. Aliment Pharmacol Ther 2020;52:292-302. [PMID: 32506695 DOI: 10.1111/apt.15808] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
23 Guzman-Prado Y, Samson O, Segal JP, Limdi JK, Hayee B. Vitamin D Therapy in Adults With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2020;26:1819-30. [PMID: 32385487 DOI: 10.1093/ibd/izaa087] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
24 van Gennep S, Evers SW, Rietdijk ST, Gielen ME, de Boer NKH, Gecse KB, Ponsioen CIJ, Duijvestein M, D'Haens GR, de Boer AGEM, Löwenberg M. High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study. Inflamm Bowel Dis 2021;27:352-63. [PMID: 32378704 DOI: 10.1093/ibd/izaa082] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
25 Levartovsky A, Ungar B, Yavzori M, Picard O, Fudim E, Eliakim R, Paul S, Roblin X, Ben-Horin S, Kopylov U. Infliximab levels and antibodies in IBD-related peripheral arthralgia. Int J Colorectal Dis 2020;35:1141-8. [PMID: 32296932 DOI: 10.1007/s00384-020-03581-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
26 Honap S, Chee D, Chapman TP, Patel M, Kent AJ, Ray S, Sharma E, Kennedy J, Cripps S, Walsh A, Goodhand JR, Ahmad T, Satsangi J, Irving PM, Kennedy NA, Begum Y, O’neill R, Mawdsley J, Samaan M, Anderson S, Sanderson J, Gordon C, Prasad S, Lin S, Chanchlani N, Elworthy C, Cairnes V, Travis S, Brain O, Palmer R, Ambrose T, Dubois P, Hayee BH, Chung-faye G, Medcalf L, Begum Y, O’neill R, Mawdsley J, Samaan M, Anderson S, Sanderson J, Gordon C, Prasad S, Lin S, Chanchlani N, Elworthy C, Cairnes V, Travis S, Brain O, Palmer R, Ambrose T, Dubois P, Hayee BH, Chung-faye G, Medcalf L; LEO [London, Exeter, Oxford] IBD Research Consortium. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. Journal of Crohn's and Colitis 2020;14:1385-93. [DOI: 10.1093/ecco-jcc/jjaa075] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
27 Dang X, Xu M, Liu D, Zhou D, Yang W. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis. PLoS One. 2020;15:e0228846. [PMID: 32182248 DOI: 10.1371/journal.pone.0228846] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
28 de Jong DC, Löwenberg M, Koumoutsos I, Ray S, Mawdsley J, Anderson S, Sanderson JD, Gecse K, Ponsioen CY, D'Haens GR, Irving PM, Samaan MA. Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. Inflamm Bowel Dis 2019;25:937-44. [PMID: 30329045 DOI: 10.1093/ibd/izy325] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
29 Lair-mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-biroulet L, Simon M, Viennot S, Bouhnik Y. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Digestive and Liver Disease 2020;52:268-73. [DOI: 10.1016/j.dld.2019.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
30 Zhao M, Bendtsen F, Petersen AM, Larsen L, Dige A, Hvas C, Seidelin JB, Burisch J. Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy-the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study. BMJ Open 2020;10:e035756. [PMID: 32102828 DOI: 10.1136/bmjopen-2019-035756] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Kim H, Venancio VP, Fang C, Dupont AW, Talcott ST, Mertens-Talcott SU. Mango (Mangifera indica L.) polyphenols reduce IL-8, GRO, and GM-SCF plasma levels and increase Lactobacillus species in a pilot study in patients with inflammatory bowel disease. Nutr Res 2020;75:85-94. [PMID: 32109839 DOI: 10.1016/j.nutres.2020.01.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
32 Ibraheim H, Samaan MA, Srinivasan A, Brain O, Digby-Bell J, Irving PM, Norman I, Jawad I, Biedermann J, Ibarra A, Kok KB, Parkes G, Rimmer J, Compot E, Parkes M, Segal J, Oppong P, Hart A, Hayee B, Powell N. Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. Ann Gastroenterol 2020;33:170-7. [PMID: 32127738 DOI: 10.20524/aog.2020.0447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
33 Cross RK, Langenberg P, Regueiro M, Schwartz DA, Tracy JK, Collins JF, Katz J, Ghazi L, Patil SA, Quezada SM, Beaulieu D, Horst SN, Russman K, Riaz M, Jambaulikar G, Sivasailam B, Quinn CC. A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol 2019;114:472-82. [PMID: 30410041 DOI: 10.1038/s41395-018-0272-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 65] [Article Influence: 17.7] [Reference Citation Analysis]
34 Sadeghi N, Mansoori A, Shayesteh A, Hashemi SJ. The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis. Phytother Res 2020;34:1123-33. [PMID: 31802559 DOI: 10.1002/ptr.6581] [Cited by in Crossref: 22] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
35 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 555] [Article Influence: 205.7] [Reference Citation Analysis]
36 Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 92] [Cited by in F6Publishing: 117] [Article Influence: 30.7] [Reference Citation Analysis]
37 Misra R, Limdi J, Cooney R, Sakuma S, Brookes M, Fogden E, Pattni S, Sharma N, Iqbal T, Munkholm P, Burisch J, Arebi N. Ethnic differences in inflammatory bowel disease: Results from the United Kingdom inception cohort epidemiology study. World J Gastroenterol 2019; 25(40): 6145-6157 [PMID: 31686769 DOI: 10.3748/wjg.v25.i40.6145] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
38 Mccombie A, Walmsley R, Barclay M, Ho C, Langlotz T, Regenbrecht H, Gray A, Visesio N, Inns S, Schultz M. A Noninferiority Randomized Clinical Trial of the Use of the Smartphone-Based Health Applications IBDsmart and IBDoc in the Care of Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases 2020;26:1098-109. [DOI: 10.1093/ibd/izz252] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
39 Ungar B, Ben-Shatach Z, Selinger L, Malik A, Albshesh A, Ben-Horin S, Eliakim R, Kopylov U, Carter D. Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease. United European Gastroenterol J 2020;8:167-74. [PMID: 32213067 DOI: 10.1177/2050640619878974] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
40 Ungar B, Ben-shatach Z, Ben-haim G, Yavzori M, Picard O, Fudim E, Kopylov U, Veyrard P, Del Tedesco É, Paul S, Eliakim R, Ben-horin S, Roblin X. Infliximab therapy intensification upon loss of response: Is there an optimal trough level? Digestive and Liver Disease 2019;51:1106-11. [DOI: 10.1016/j.dld.2019.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Samaan MA, Birdi S, Morales MS, Honap S, Tamilarasan AG, Cunningham G, Koumoutsos I, Ray S, Mawdsley J, Anderson SHC, Sanderson J, Irving PM. Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response. Frontline Gastroenterol 2020;11:188-93. [PMID: 32419909 DOI: 10.1136/flgastro-2019-101259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
42 Ossum AM, Palm Ø, Cvancarova M, Bernklev T, Jahnsen J, Moum B, Høivik ML; IBSEN Study Group. The Impact of Spondyloarthritis and Joint Symptoms on Health-Related Quality of Life and Fatigue in IBD Patients. Results From a Population-Based Inception Cohort (20-Year Follow-up in the Ibsen Study). Inflammatory Bowel Diseases 2020;26:114-24. [DOI: 10.1093/ibd/izz105] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
43 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 91] [Article Influence: 16.7] [Reference Citation Analysis]
44 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 783] [Article Influence: 170.5] [Reference Citation Analysis]
45 Jordan C, Hayee B, Chalder T. Cognitive behaviour therapy for distress in people with inflammatory bowel disease: A benchmarking study. Clin Psychol Psychother 2019;26:14-23. [PMID: 30207003 DOI: 10.1002/cpp.2326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
46 Geiss T, Schaefert RM, Berens S, Hoffmann P, Gauss A. Risk of depression in patients with inflammatory bowel disease: Risk factors for depression in IBD. Journal of Digestive Diseases 2018;19:456-67. [DOI: 10.1111/1751-2980.12644] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
47 Willemze RA, Bakker T, Pippias M, Ponsioen CY, de Jonge WJ. β-Blocker use is associated with a higher relapse risk of inflammatory bowel disease: a Dutch retrospective case-control study. Eur J Gastroenterol Hepatol 2018;30:161-6. [PMID: 29111997 DOI: 10.1097/MEG.0000000000001016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
48 Probert CS, Sebastian S, Gaya DR, Hamlin PJ, Gillespie G, Rose A, Tate H, Wheeler C, Irving PM. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis). BMJ Open Gastroenterol 2018;5:e000212. [PMID: 30002864 DOI: 10.1136/bmjgast-2018-000212] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
49 Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis 2017;11:1317-25. [PMID: 28981846 DOI: 10.1093/ecco-jcc/jjx093] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
50 Ungar B, Engel T, Yablecovitch D, Lahat A, Lang A, Avidan B, Har-noy O, Carter D, Levhar N, Selinger L, Neuman S, Natour OH, Yavzori M, Fudim E, Picard O, Kopylov U, Chowers Y, Naftali T, Broide E, Shachar E, Eliakim R, Ben-horin S. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study. American Journal of Gastroenterology 2018;113:890-8. [DOI: 10.1038/s41395-018-0073-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 8.3] [Reference Citation Analysis]
51 Helavirta I, Hyöty M, Oksanen P, Huhtala H, Haapamäki J, Aitola P. Health-Related Quality of Life after Restorative Proctocolectomy: A Cross-Sectional Study. Scand J Surg 2018;107:315-21. [PMID: 29774794 DOI: 10.1177/1457496918772362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, Coscas D, Waterman M, Haj-natour O, Orbach-zingboim N, Mao R, Chen M, Chowers Y, Eliakim R, Ben-horin S. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 2018;16:697-705.e7. [DOI: 10.1016/j.cgh.2017.11.050] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 18.5] [Reference Citation Analysis]
53 MacFarlane A, Galvin R, O'Sullivan M, McInerney C, Meagher E, Burke D, LeMaster JW. Participatory methods for research prioritization in primary care: an analysis of the World Café approach in Ireland and the USA. Fam Pract 2017;34:278-84. [PMID: 27677298 DOI: 10.1093/fampra/cmw104] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
54 Graff LA, Sexton KA, Walker JR, Clara I, Targownik LE, Bernstein CN. Validating a Measure of Patient Self-efficacy in Disease Self-management Using a Population-based IBD Cohort: The IBD Self-efficacy Scale. Inflamm Bowel Dis 2016;22:2165-72. [PMID: 27542132 DOI: 10.1097/MIB.0000000000000856] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
55 Huppertz-Hauss G, Lie Høivik M, Jelsness-Jørgensen LP, Henriksen M, Høie O, Jahnsen J, Hoff G, Moum B, Bernklev T. Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis: Results from the IBSEN Study. Inflamm Bowel Dis 2016;22:1679-87. [PMID: 27206016 DOI: 10.1097/MIB.0000000000000806] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
56 Pavlidis P, Stamoulos P, Abdulrehman A, Kerr P, Bull C, Duley J, Ansari A. Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study. Inflamm Bowel Dis. 2016;22:1639-1646. [PMID: 27271488 DOI: 10.1097/mib.0000000000000827] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
57 Mohammed Vashist N, Samaan M, Mosli MH, Parker CE, MacDonald JK, Nelson SA, Zou GY, Feagan BG, Khanna R, Jairath V. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 2018;1:CD011450. [PMID: 29338066 DOI: 10.1002/14651858.CD011450.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
58 Gubatan J, Mitsuhashi S, Longhi MS, Zenlea T, Rosenberg L, Robson S, Moss AC. Higher serum vitamin D levels are associated with protective serum cytokine profiles in patients with ulcerative colitis. Cytokine. 2018;103:38-45. [PMID: 29324259 DOI: 10.1016/j.cyto.2017.12.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
59 Bar-yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, Fudim E, Kopylov U, Eliakim R, Ben-horin S, Chowers Y, Ungar B. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther 2018;47:212-8. [DOI: 10.1111/apt.14410] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
60 Kristensen V, Røseth A, Ahmad T, Skar V, Moum B. Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis. Gastroenterol Res Pract 2017;2017:2098293. [PMID: 29225617 DOI: 10.1155/2017/2098293] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
61 Samaan MA, Pavlidis P, Digby-Bell J, Johnston EL, Dhillon A, Paramsothy R, Akintimehin AO, Medcalf L, Chung-Faye G, DuBois P, Koumoutsos I, Powell N, Anderson SHC, Sanderson J, Hayee BH, Irving PM. Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2018;9:221-231. [PMID: 30047549 DOI: 10.1136/flgastro-2017-100895] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
62 Jordan C, Ohlsen R, Hayee B, Chalder T. A qualitative study exploring the experience of people with IBD and elevated symptoms of anxiety and low mood and the type of psychological help they would like. Psychol Health 2018;33:634-51. [PMID: 28948842 DOI: 10.1080/08870446.2017.1381958] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
63 Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
64 Mcphee G. Cognitive behaviour therapy and objective assessments in chronic fatigue syndrome. J Health Psychol 2017;22:1181-6. [DOI: 10.1177/1359105317707215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
65 Hibi T, Imai Y, Senoo A, Ohta K, Ukyo Y. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). J Gastroenterol 2017;52:1101-11. [PMID: 28324167 DOI: 10.1007/s00535-017-1326-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
66 Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.Dig Liver Dis. 2017;49:604-617. [PMID: 28254463 DOI: 10.1016/j.dld.2017.01.161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
67 Sands BE, Joshi S, Haddad J, Freudenberg JM, Oommen DE, Hoffmann E, McCallum SW, Jacobson E. Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis. Inflamm Bowel Dis 2016;22:607-14. [PMID: 26595549 DOI: 10.1097/MIB.0000000000000597] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
68 Opheim R, Lie Høivik M, Bernklev T, Jelsness-Jørgensen LP, Moum B. The Use of Complementary and Alternative Medicine among Patients with Inflammatory Bowel Disease Is Associated with Reduced Health-Related Quality of Life. Gastroenterol Res Pract 2016;2016:6453657. [PMID: 28003821 DOI: 10.1155/2016/6453657] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
69 Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP, Opheim R, Henriksen M, Høie O, Hovde Ø, Kempski-Monstad I, Solberg IC, Jahnsen J, Hoff G, Moum B, Bernklev T. Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study. Scand J Gastroenterol 2017;52:351-8. [PMID: 27852169 DOI: 10.1080/00365521.2016.1256425] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
70 Ungar B, Kopylov U, Engel T, Yavzori M, Fudim E, Picard O, Lang A, Williet N, Paul S, Chowers Y, Bar-gil Shitrit A, Eliakim R, Ben-horin S, Roblin X. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther 2017;45:276-82. [DOI: 10.1111/apt.13862] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 12.7] [Reference Citation Analysis]
71 Menys A, Makanyanga J, Plumb A, Bhatnagar G, Atkinson D, Emmanuel A, Taylor SA. Aberrant Motility in Unaffected Small Bowel is Linked to Inflammatory Burden and Patient Symptoms in Crohn's Disease. Inflamm Bowel Dis. 2016;22:424-432. [PMID: 26509756 DOI: 10.1097/mib.0000000000000601] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
72 McCombie A, Gearry R, Andrews J, Mulder R, Mikocka-Walus A. Does Computerized Cognitive Behavioral Therapy Help People with Inflammatory Bowel Disease? A Randomized Controlled Trial. Inflamm Bowel Dis. 2016;22:171-181. [PMID: 26360545 DOI: 10.1097/mib.0000000000000567] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 8.8] [Reference Citation Analysis]
73 Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2016;22:224-33. [PMID: 26457382 DOI: 10.1097/MIB.0000000000000589] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
74 Gauss A, Geib T, Hinz U, Schaefert R, Zwickel P, Zawierucha A, Stremmel W, Klute L. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease. Medicine (Baltimore). 2016;95:e3477. [PMID: 27100452 DOI: 10.1097/md.0000000000003477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
75 de Groof EJ, Rossen NG, van Rhijn BD, Karregat EP, Boonstra K, Hageman I, Bennebroek Evertsz F, Kingma PJ, Naber AH, van den Brande JH, Mallant-hent RC, Mundt MW, D’haens GR, Ponsioen CY. Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands: . European Journal of Gastroenterology & Hepatology 2016;28:1065-72. [DOI: 10.1097/meg.0000000000000660] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
76 Samaan MA, Pavlidis P, Johnston E, Warner B, Digby-Bell J, Koumoutsos I, Fong S, Goldberg R, Patel K, Gulati S. Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2017;8:196-202. [PMID: 28839909 DOI: 10.1136/flgastro-2016-100720] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
77 McCombie AM, Mulder RT, Gearry RB. Coping Strategies and Psychological Outcomes of Patients with Inflammatory Bowel Disease in the First 6 Months After Diagnosis. Inflamm Bowel Dis 2015;21:2272-80. [PMID: 26099065 DOI: 10.1097/MIB.0000000000000476] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
78 Gubatan J, Mitsuhashi S, Zenlea T, Rosenberg L, Robson S, Moss AC. Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2017; 15: 240-246. e1. [PMID: 27266980 DOI: 10.1016/j.cgh.2016.05.035] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 10.3] [Reference Citation Analysis]
79 Lang A, Salomon N, Ben-Horin S. Reply. Clin Gastroenterol Hepatol 2016;14:913-913.e2. [PMID: 26940282 DOI: 10.1016/j.cgh.2016.02.025] [Reference Citation Analysis]
80 van Tuyl LH, Michaud K. Patient-Reported Outcomes in Rheumatoid Arthritis. Rheumatic Disease Clinics of North America 2016;42:219-37. [DOI: 10.1016/j.rdc.2016.01.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
81 Zenlea T, Yee EU, Rosenberg L, Boyle M, Nanda KS, Wolf JL, Falchuk KR, Cheifetz AS, Goldsmith JD, Moss AC. Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. American Journal of Gastroenterology 2016;111:685-90. [DOI: 10.1038/ajg.2016.50] [Cited by in Crossref: 97] [Cited by in F6Publishing: 110] [Article Influence: 16.2] [Reference Citation Analysis]
82 Ungar B, Mazor Y, Weisshof R, Yanai H, Ron Y, Goren I, Waizbard A, Yavzori M, Fudim E, Picard O, Loebstein R, Kopylov U, Dotan I, Chowers Y, Eliakim R, Ben-horin S. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther 2016;43:1293-9. [DOI: 10.1111/apt.13631] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
83 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 220] [Cited by in F6Publishing: 198] [Article Influence: 36.7] [Reference Citation Analysis]
84 Langhorst J, Boone J, Lauche R, Rueffer A, Dobos G. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial. J Crohns Colitis 2016;10:786-94. [PMID: 26874351 DOI: 10.1093/ecco-jcc/jjw044] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
85 Marín-jiménez I, Nos P, Domènech E, Riestra S, Gisbert JP, Calvet X, Cortés X, Iglesias E, Huguet JM, Taxonera C, Fernández R, Carpio D, Gutiérrez A, Guardiola J, Laria LC, Sicilia B, Bujanda L, Cea-calvo L, Romero C, Rincón Ó, Juliá B, Panés J. Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. American Journal of Gastroenterology 2016;111:261-8. [DOI: 10.1038/ajg.2015.403] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
86 Nuki Y, Esaki M, Asano K, Maehata Y, Umeno J, Moriyama T, Nakamura S, Matsumoto T, Kitazono T. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. Scand J Gastroenterol. 2016;51:700-705. [PMID: 26818468 DOI: 10.3109/00365521.2016.1138239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
87 Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, Loebstein R, Chowers Y, Eliakim R, Kopylov U, Ben-Horin S. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2016;14:550-557.e2. [PMID: 26538204 DOI: 10.1016/j.cgh.2015.10.025] [Cited by in Crossref: 242] [Cited by in F6Publishing: 225] [Article Influence: 34.6] [Reference Citation Analysis]
88 Ng SC, Zeng Z, Niewiadomski O, Tang W, Bell S, Kamm MA, Hu P, de Silva HJ, Niriella MA, Udara WS. Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia. Gastroenterology. 2016;150:86-95.e3; quiz e13-4. [PMID: 26385074 DOI: 10.1053/j.gastro.2015.09.005] [Cited by in Crossref: 64] [Cited by in F6Publishing: 72] [Article Influence: 9.1] [Reference Citation Analysis]
89 Schoultz M, Atherton I, Watson A. Mindfulness-based cognitive therapy for inflammatory bowel disease patients: findings from an exploratory pilot randomised controlled trial. Trials. 2015;16:379. [PMID: 26303912 DOI: 10.1186/s13063-015-0909-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
90 Melmed GY, Pandak WM, Casey K, Abraham B, Valentine J, Schwartz D, Awais D, Bassan I, Lichtiger S, Sands B, Hanauer S, Richards R, Oikonomou I, Parekh N, Targan S, Johnson K, Hariri R, Fischkoff S. Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohnʼs Disease: A Phase 1b/2a Study. Inflammatory Bowel Diseases 2015;21:1809-16. [DOI: 10.1097/mib.0000000000000441] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
91 Ungar B, Haj-Natour O, Kopylov U, Yavzori M, Fudim E, Picard O, Loebstein R, Lahat A, Maor Y, Avidan B, Lang A, Weiss B, Chowers Y, Eliakim R, Ben-Horin S. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure. Medicine (Baltimore) 2015;94:e673. [PMID: 25950682 DOI: 10.1097/MD.0000000000000673] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
92 Pavlidis P, Ansari A, Duley J, Oancea I, Florin T. Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study. Inflamm Bowel Dis. 2014;20:2239-2246. [PMID: 25230165 DOI: 10.1097/mib.0000000000000206] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
93 Kyaw MH, Moshkovska T, Mayberry J. A prospective, randomized, controlled, exploratory study of comprehensive dietary advice in ulcerative colitis: impact on disease activity and quality of life. Eur J Gastroenterol Hepatol. 2014;26:910-917. [PMID: 24942954 DOI: 10.1097/meg.0000000000000127] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
94 Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, Löwenberg M, van den Brink GR, Mathus-Vliegen EM, de Vos WM. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015;149:110-118.e4. [PMID: 25836986 DOI: 10.1053/j.gastro.2015.03.045] [Cited by in Crossref: 490] [Cited by in F6Publishing: 500] [Article Influence: 70.0] [Reference Citation Analysis]
95 Samaan MA, Mosli MH, Sandborn WJ, Feagan BG, D' Haens GR, Dubcenco E, Baker KA, Levesque BG. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014;20:1465-1471. [PMID: 24831558 DOI: 10.1097/mib.0000000000000046] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
96 Cross RK, Jambaulikar G, Langenberg P, Tracy JK, Collins JF, Katz J, Regueiro M, Schwartz DA, Quinn CC. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial. Contemp Clin Trials 2015;42:132-44. [PMID: 25812483 DOI: 10.1016/j.cct.2015.03.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
97 Mawe GM. Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon. J Clin Invest. 2015;125:949-955. [PMID: 25729851 DOI: 10.1172/jci76306] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 7.7] [Reference Citation Analysis]
98 Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2015;13:1444-9.e1. [PMID: 25724700 DOI: 10.1016/j.cgh.2015.02.019] [Cited by in Crossref: 194] [Cited by in F6Publishing: 160] [Article Influence: 27.7] [Reference Citation Analysis]
99 Hosseini SV, Jafari P, Taghavi SA, Safarpour AR, Rezaianzadeh A, Moini M, Mehrabi M. Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis. Iran Red Crescent Med J 2015;17:e22796. [PMID: 25793117 DOI: 10.5812/ircmj.22796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
100 Ungar B, Anafy A, Yanai H, Ron Y, Yavzori M, Picard O, Fudim E, Loebstein R, Kopylov U, Chowers Y, Dotan I, Eliakim R, Ben-Horin S. Significance of low level infliximab in the absence of anti-infliximab antibodies. World J Gastroenterol 2015; 21(6): 1907-1914 [PMID: 25684959 DOI: 10.3748/wjg.v21.i6.1907] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
101 Tabibian A, Tabibian JH, Beckman LJ, Raffals LL, Papadakis KA, Kane SV. Predictors of health-related quality of life and adherence in Crohn's disease and ulcerative colitis: implications for clinical management. Dig Dis Sci. 2015;60:1366-1374. [PMID: 25559754 DOI: 10.1007/s10620-014-3471-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 8.9] [Reference Citation Analysis]
102 Bewtra M, Brensinger CM, Tomov VT, Hoang TB, Sokach CE, Siegel CA, Lewis JD. An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis. 2014;20:1070-1078. [PMID: 24810138 DOI: 10.1097/mib.0000000000000053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
103 Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Fecal calprotectin testing can identify ineffective colorectal cancer surveillance procedures in patients with longstanding colitis. Inflamm Bowel Dis. 2014;20:1079-1084. [PMID: 24788218 DOI: 10.1097/MIB.0000000000000054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
104 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, van Assche G. [Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]. Rev Gastroenterol Mex 2014;79:263-89. [PMID: 25487134 DOI: 10.1016/j.rgmx.2014.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
105 Pedersen N, Thielsen P, Martinsen L, Bennedsen M, Haaber A, Langholz E, Végh Z, Duricova D, Jess T, Bell S, Burisch J, Munkholm P. eHealth: Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis. Inflammatory Bowel Diseases 2014;20:2276-85. [DOI: 10.1097/mib.0000000000000199] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
106 Alrubaiy L, Dodds P, Hutchings HA, Russell IT, Watkins A, Williams JG. Development and validation of a new disease severity index: the Inflammatory Bowel Disease Index (IBDEX). Frontline Gastroenterol 2015;6:161-8. [PMID: 28839806 DOI: 10.1136/flgastro-2014-100530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
107 Burisch J, Pedersen N, Cukovic-Cavka S, Turk N, Kaimakliotis I, Duricova D, Shonová O, Vind I, Avnstrøm S, Thorsgaard N. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis. 2014;20:36-46. [PMID: 24252978 DOI: 10.1097/01.mib.0000436277.13917.c4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
108 Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Eliakim R, Ben-Horin S; ABIRISK consortium. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014;63:1258-64. [PMID: 24041539 DOI: 10.1136/gutjnl-2013-305259] [Cited by in Crossref: 211] [Cited by in F6Publishing: 194] [Article Influence: 26.4] [Reference Citation Analysis]
109 Brierley SM, Linden DR. Neuroplasticity and dysfunction after gastrointestinal inflammation. Nat Rev Gastroenterol Hepatol 2014;11:611-27. [PMID: 25001973 DOI: 10.1038/nrgastro.2014.103] [Cited by in Crossref: 168] [Cited by in F6Publishing: 156] [Article Influence: 21.0] [Reference Citation Analysis]
110 Bodger K, Ormerod C, Shackcloth D, Harrison M; IBD Control Collaborative. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut 2014;63:1092-102. [PMID: 24107590 DOI: 10.1136/gutjnl-2013-305600] [Cited by in Crossref: 92] [Cited by in F6Publishing: 79] [Article Influence: 11.5] [Reference Citation Analysis]
111 Krag A, Munkholm P, Israelsen H, von Ryberg B, Andersen KK, Bendtsen F. Profermin is efficacious in patients with active ulcerative colitis--a randomized controlled trial. Inflamm Bowel Dis 2013;19:2584-92. [PMID: 24108114 DOI: 10.1097/01.MIB.0000437046.26036.db] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
112 Karner M, Kocjan A, Stein J, Schreiber S, von Boyen G, Uebel P, Schmidt C, Kupcinskas L, Dina I, Zuelch F, Keilhauer G, Stremmel W. First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol. 2014;109:1041-1051. [PMID: 24796768 DOI: 10.1038/ajg.2014.104] [Cited by in Crossref: 57] [Cited by in F6Publishing: 65] [Article Influence: 7.1] [Reference Citation Analysis]
113 Bennebroek Evertsz' F, Nieuwkerk PT, Stokkers PC, Ponsioen CY, Bockting CL, Sanderman R, Sprangers MA. The Patient Simple Clinical Colitis Activity Index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: A comparison of the P-SCCAI with clinician-based SCCAI and biological markers. Journal of Crohn's and Colitis 2013;7:890-900. [DOI: 10.1016/j.crohns.2012.11.007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
114 Walmsley RS, Casey P. On the physician-completed and the patient-completed Simple Clinical Colitis Activity Index (SCCAI). Journal of Crohn's and Colitis 2013;7:930-1. [DOI: 10.1016/j.crohns.2013.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
115 Goldenberg BA, Graff LA, Clara I, Zarychanski R, Walker JR, Carr R, Rogala L, Miller N, Bernstein CN. Is iron deficiency in the absence of anemia associated with fatigue in inflammatory bowel disease? Am J Gastroenterol. 2013;108:1392-1397. [PMID: 24005345 DOI: 10.1038/ajg.2013.14] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
116 Walsh AJ, Ghosh A, Brain AO, Buchel O, Burger D, Thomas S, White L, Collins GS, Keshav S, Travis SP. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2014;8:318-325. [PMID: 24120021 DOI: 10.1016/j.crohns.2013.09.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
117 Mayer L, Pandak WM, Melmed GY, Hanauer SB, Johnson K, Payne D, Faleck H, Hariri RJ, Fischkoff SA. Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study. Inflamm Bowel Dis. 2013;19:754-760. [PMID: 23429460 DOI: 10.1097/mib.0b013e31827f27df] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
118 Rosenberg L, Lawlor GO, Zenlea T, Goldsmith JD, Gifford A, Falchuk KR, Wolf JL, Cheifetz AS, Robson SC, Moss AC. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013;19:779-784. [PMID: 23446338 DOI: 10.1097/mib.0b013e3182802b0e] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
119 Opheim R, Fagermoen MS, Bernklev T, Jelsness-Jorgensen LP, Moum B. Fatigue interference with daily living among patients with inflammatory bowel disease. Qual Life Res 2014;23:707-17. [PMID: 23975381 DOI: 10.1007/s11136-013-0508-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
120 Keefer L, Taft TH, Kiebles JL, Martinovich Z, Barrett TA, Palsson OS. Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. Aliment Pharmacol Ther. 2013;38:761-771. [PMID: 23957526 DOI: 10.1111/apt.12449] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 7.8] [Reference Citation Analysis]
121 Pedersen N, Bortoli A, Duricova D, D Inca R, Panelli MR, Gisbert JP, Zoli G, López-Sanromán A, Castiglione F, Riegler G. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther. 2013;38:501-512. [PMID: 23855425 DOI: 10.1111/apt.12412] [Cited by in Crossref: 109] [Cited by in F6Publishing: 91] [Article Influence: 12.1] [Reference Citation Analysis]
122 Rosenberg L, Nanda KS, Zenlea T, Gifford A, Lawlor GO, Falchuk KR, Wolf JL, Cheifetz AS, Goldsmith JD, Moss AC. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol. 2013;11:991-996. [PMID: 23591275 DOI: 10.1016/j.cgh.2013.02.030] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 9.8] [Reference Citation Analysis]
123 Samuel S, Bruining DH, Loftus EV, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR, Sandborn WJ. Validation of the Ulcerative Colitis Colonoscopic Index of Severity and Its Correlation With Disease Activity Measures. Clinical Gastroenterology and Hepatology 2013;11:49-54.e1. [DOI: 10.1016/j.cgh.2012.08.003] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 10.2] [Reference Citation Analysis]
124 Khanna R, Feagan BG. Through the Looking Glass: A Journey Toward Optimal Endoscopic Assessment of Disease Activity in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2013;11:55-6. [DOI: 10.1016/j.cgh.2012.09.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
125 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990. [PMID: 23040452 DOI: 10.1016/j.crohns.2012.09.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 526] [Article Influence: 53.9] [Reference Citation Analysis]
126 Casellas F, Barreiro de Acosta M, Iglesias M, Robles V, Nos P, Aguas M, Riestra S, de Francisco R, Papo M, Borruel N. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:762-769. [PMID: 22517240 DOI: 10.1097/meg.0b013e32835414b2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
127 Jelsness-Jørgensen LP, Bernklev T, Moum B. Fatigue and disease-related worries among inflammatory bowel disease patients in remission; is it a reflection of coexisting IBS-like symptoms? A short report. J Psychosom Res. 2012;73:469-472. [PMID: 23148817 DOI: 10.1016/j.jpsychores.2012.08.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
128 Krag A, Israelsen H, Ryberg BV, Andersen KK, Bendtsen F. Safety and efficacy of Profermin® to induce remission in ulcerative colitis. World J Gastroenterol 2012; 18(15): 1773-1780 [PMID: 22553401 DOI: 10.3748/wjg.v18.i15.1773] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
129 Lee JJ, Colman RJ, Mitchell PD, Atmadja ML, Bousvaros A, Lightdale JR. Agreement between patient- and physician-completed Pediatric Ulcerative Colitis Activity Index scores. J Pediatr Gastroenterol Nutr. 2011;52:708-713. [PMID: 21593644 DOI: 10.1097/mpg.0b013e3182099018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
130 Høivik ML, Bernklev T, Solberg IC, Cvancarova M, Lygren I, Jahnsen J, Moum B. Patients with Crohn’s disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study. J Crohns Colitis. 2012;6:441-453. [PMID: 22398064 DOI: 10.1016/j.crohns.2011.10.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
131 Bregnbak D, Mortensen C, Bendtsen F. Infliximab and complications after colectomy in patients with ulcerative colitis. J Crohns Colitis. 2012;6:281-286. [PMID: 22405163 DOI: 10.1016/j.crohns.2011.08.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
132 Hoivik ML, Moum B, Solberg IC, Cvancarova M, Hoie O, Vatn MH, Bernklev T; IBSEN Study Group. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm Bowel Dis 2012;18:1540-9. [PMID: 21936030 DOI: 10.1002/ibd.21863] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]
133 Travis SPL, Higgins PDR, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O’morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D’haens G. Review article: defining remission in ulcerative colitis: Review: remission in ulcerative colitis. Alimentary Pharmacology & Therapeutics 2011;34:113-24. [DOI: 10.1111/j.1365-2036.2011.04701.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 10.9] [Reference Citation Analysis]
134 Orchard TR, van der Geest SA, Travis SP. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis-new light on a familiar question. Aliment Pharmacol Ther. 2011;33:1028-1035. [PMID: 21385195 DOI: 10.1111/j.1365-2036.2011.04620.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
135 Rath T, Roderfeld M, Halwe JM, Tschuschner A, Roeb E, Graf J. Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis. Scand J Gastroenterol. 2010;45:1186-1196. [PMID: 20568971 DOI: 10.3109/00365521.2010.499961] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
136 Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011;33:672-678. [PMID: 21255059 DOI: 10.1111/j.1365-2036.2010.04575.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 5.6] [Reference Citation Analysis]
137 Graff LA, Vincent N, Walker JR, Clara I, Carr R, Ediger J, Miller N, Rogala L, Rawsthorne P, Lix L, Bernstein CN. A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1882-1889. [PMID: 21830266 DOI: 10.1002/ibd.21580] [Cited by in Crossref: 176] [Cited by in F6Publishing: 163] [Article Influence: 14.7] [Reference Citation Analysis]
138 Stewart RJ, Caird J, Oliver K, Oliver S. Patients' and clinicians' research priorities. Health Expect 2011;14:439-48. [PMID: 21176014 DOI: 10.1111/j.1369-7625.2010.00648.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 79] [Article Influence: 5.1] [Reference Citation Analysis]
139 Huamán J, Casellas F, Borruel N, Peláez A, Torrejón A, Castells I, Masachs M, Varela E, Guarner F. Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life. Journal of Crohn's and Colitis 2010;4:637-41. [DOI: 10.1016/j.crohns.2010.07.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
140 Elkjaer M, Burisch J, Avnstrøm S, Lynge E, Munkholm P. Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. Eur J Gastroenterol Hepatol. 2010;22:695-704. [PMID: 19543101 DOI: 10.1097/meg.0b013e32832e0a18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
141 Chebli LA, Chaves LD, Pimentel FF, Guerra DM, Barros RM, Gaburri PD, Zanini A, Chebli JM. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010;16:613-619. [PMID: 19705415 DOI: 10.1002/ibd.21083] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
142 Novacek G, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Miehsler W, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Eichinger S. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010;139:779-787, 787.e1. [PMID: 20546736 DOI: 10.1053/j.gastro.2010.05.026] [Cited by in Crossref: 153] [Cited by in F6Publishing: 149] [Article Influence: 12.8] [Reference Citation Analysis]
143 Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010;10:13. [PMID: 20398311 DOI: 10.1186/1472-6882-10-13] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 10.2] [Reference Citation Analysis]
144 Turner D, Griffiths AM, Mack D, Otley AR, Seow CH, Steinhart HA, Silverberg MS, Hyams J, Guyatt GH. Assessing disease activity in ulcerative colitis: Patients or their physicians? Inflammatory Bowel Diseases 2010;16:651-6. [DOI: 10.1002/ibd.21088] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
145 Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010;138:1286-1296, 1286-1296. [PMID: 20064514 DOI: 10.1053/j.gastro.2009.12.054] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 6.9] [Reference Citation Analysis]
146 Cross RK, Finkelstein J. Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis. Clin Trials. 2009;6:649-657. [PMID: 19822631 DOI: 10.1177/1740774509346978] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
147 Rubenstein JH, Waljee AK, Jeter JM, Velayos FS, Ladabaum U, Higgins PD. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol 2009;104:2222-32. [PMID: 19491824 DOI: 10.1038/ajg.2009.264] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
148 Lam MY, Lee H, Bright R, Korzenik JR, Sands BE. Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire. Inflamm Bowel Dis. 2009;15:599-607. [PMID: 19023897 DOI: 10.1002/ibd.20803] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
149 Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081-1088. [PMID: 19577010 DOI: 10.1016/j.cgh.2009.06.024] [Cited by in Crossref: 121] [Cited by in F6Publishing: 108] [Article Influence: 9.3] [Reference Citation Analysis]
150 Clara I, Lix LM, Walker JR, Graff LA, Miller N, Rogala L, Rawsthorne P, Bernstein CN. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol 2009;104:1754-63. [PMID: 19455122 DOI: 10.1038/ajg.2009.197] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 6.1] [Reference Citation Analysis]
151 Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660-1666. [PMID: 18623174 DOI: 10.1002/ibd.20520] [Cited by in Crossref: 463] [Cited by in F6Publishing: 436] [Article Influence: 35.6] [Reference Citation Analysis]
152 Irvine EJ, Yeh C, Ramsey D, Stirling AL, Higgins PDR. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2008;28:1278-86. [DOI: 10.1111/j.1365-2036.2008.03854.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
153 Bossa F, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B, Serafini S, Damonte G, De Santo E, Andriulli A, Annese V. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol 2008;103:2509-16. [PMID: 18721243 DOI: 10.1111/j.1572-0241.2008.02103.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]
154 Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis. 2008;14:554-565. [PMID: 17973299 DOI: 10.1002/ibd.20301] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 6.4] [Reference Citation Analysis]
155 Witte TN, Ginsberg AL. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can J Gastroenterol 2008;22:181-5. [PMID: 18299738 DOI: 10.1155/2008/870981] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
156 Nysæter G, Berstad A. Live Typhoid Vaccine for IBD-Patients–-Well Tolerated and with Possible Therapeutic Effect. Drug Target�Insights 2008;3:DTI.S701. [DOI: 10.4137/dti.s701] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
157 Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis. 2008;2:1-23. [PMID: 21172194 DOI: 10.1016/j.crohns.2007.11.001] [Cited by in Crossref: 353] [Cited by in F6Publishing: 333] [Article Influence: 25.2] [Reference Citation Analysis]
158 Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit. 2007;29:619-625. [PMID: 17898653 DOI: 10.1097/ftd.0b013e31811f39bb] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
159 Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008;134:688-695. [PMID: 18325386 DOI: 10.1053/j.gastro.2007.12.012] [Cited by in Crossref: 145] [Cited by in F6Publishing: 150] [Article Influence: 9.7] [Reference Citation Analysis]
160 Rhodes JM, Robinson R, Beales I, Pugh S, Dickinson R, Dronfield M, Speirs CJ, Wilkinson P, Wilkinson SP. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther 2008;27:228-40. [PMID: 17988236 DOI: 10.1111/j.1365-2036.2007.03569.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
161 Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 2007;8:17. [PMID: 17592647 DOI: 10.1186/1745-6215-8-17] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 5.3] [Reference Citation Analysis]
162 D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786. [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038] [Cited by in Crossref: 629] [Cited by in F6Publishing: 627] [Article Influence: 39.3] [Reference Citation Analysis]
163 Higgins PDR, Leung J, Schwartz M, Mapili J, Wren PA, Zimmermann EM. The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis: QUANTITATIVE VALIDITY OF THE SCCAI AND SEO INDEX IN UC. Alimentary Pharmacology & Therapeutics 2007;25:333-42. [DOI: 10.1111/j.1365-2036.2006.03205.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
164 Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of Life After Proctocolectomy With Ileoanal Anastomosis for Patients With Ulcerative Colitis: . Journal of Clinical Gastroenterology 2006;40:669-77. [DOI: 10.1097/00004836-200609000-00002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]